GS
SUPN icon

George Soros’s Supernus Pharmaceuticals SUPN Stock Holding History

George Soros’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-107,308
Closed -$1.3M – 288
2015
Q1 		$1.3M Buy
+107,308
New +$1.01M 0.01% 201

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

George Soros's SUPN Position: Q2 2015 in Review

George Soros sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 107,308 shares — an estimated $1.3M sold.

George Soros first reported a position in SUPN in Q1 2015 and held it in 1 quarter. The position peaked at $1.3M in Q1 2015. 166 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • George Soros reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • George Soros sold 107,308 Supernus Pharmaceuticals shares in Q2 2015, an estimated $1.3M.
  • George Soros first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • George Soros's Supernus Pharmaceuticals position peaked at $1.3M in Q1 2015.
  • 166 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Soros Fund Management's 13F filing for Q2 2015, filed 14 Aug 2015.